The Medical Travel Company Raises $4.5M to Fix Medical Tourism for UK Patients Seeking Treatment in India

October 7, 2025

The Medical Travel Company (TMTC), the UK and India-based medical travel startup, raised $4.5 million (£3.3 million) in seed funding in October 2025. The round was led by Nexus Venture Partners, with participation from 4CAST — the athlete-led investment collective co-founded by England Test captain Ben Stokes, fast bowler Jofra Archer, and Indian cricketer KL Rahul — and additional angel investors including the founders of Swiggy, Tracxn, Innov8, Smile Group, and V3 Ventures. The capital will fund the expansion of TMTC’s UK-India operations, enhancement of its digital patient management platform, deepening of clinical partnerships, and preparation for scaling into the US, Canada, Europe, and Australia.

Medical tourism is a large but persistently broken industry. The global market is estimated at $100 billion annually and growing, driven by the gap between what patients in high-cost healthcare systems pay for elective procedures and what the same procedures cost in high-quality international facilities. In the UK, that gap is acute. As of mid-2025, approximately 7.7 million people are on NHS waiting lists for elective procedures — primarily in orthopaedics, dental, IVF, gynaecology, ophthalmology, and urology. For those who can’t afford UK private care and can’t wait years for NHS treatment, medical travel to India has become a practical option: major Indian hospital groups including Fortis, Max Healthcare, and Nova IVF Fertility offer internationally accredited (JCI, NABH) care at 60-70% lower cost than UK private rates.

But the experience of navigating medical tourism without institutional support has historically been unreliable. Patients face fragmented care coordination, opaque pricing, inconsistent quality standards, and — most critically — no structured aftercare or insurance coverage when they return to the UK. TMTC was founded in 2024 by Sahil Jain and Ankit Mehrotra, the co-founders of Dineout, the restaurant technology platform acquired by Swiggy in 2022 for $200 million, to solve this with a full-stack platform that addresses every stage of the medical travel journey. The company provides a UK doctor who remains involved before, during, and after treatment; treatment at globally accredited Indian hospitals with internationally trained surgeons; fully managed logistics and personalised, all-inclusive aftercare; and crucially, the world’s first 12-month post-surgery insurance policy valid in the UK at a network of private hospitals — covering complications that arise after the patient returns home.

Nexus Venture Partners’ lead investment reflects the firm’s thesis that founder-market fit is the primary predictor of success in consumer-facing platforms requiring deep trust. Pratik Poddar of Nexus described Jain and Mehrotra as “uniquely positioned to build trust and capture this opportunity” given their experience scaling Dineout, a platform that also required overcoming consumer hesitation about a high-consideration transaction. The 4CAST participation from Stokes and Archer adds both consumer credibility — internationally recognised athletes with direct experience of high-quality medical care in India through their IPL commitments — and access to the wellness and healthcare network that professional sport uniquely provides.

The addressable market is substantial: over 500,000 UK residents already travel abroad for medical care annually, and the gap between NHS waiting list reality and the affordability of quality Indian care is structural rather than cyclical. TMTC was named to the Forbes India DGEMS 2025 Select 200 list of companies with strong global potential, reflecting growing recognition of the company’s ambition to build healthcare infrastructure across borders.

Sources